VCEL Vericel Corporation

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO & VP of Corporate Development, will present the latest company overview at the Ladenburg Thalmann 2019 Healthcare Conference in New York on Tuesday, September 24, 2019 at 11:00am Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com

About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets.  The company markets two cell therapy products in the United States.  MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.  Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.  The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.  For more information, please visit the company's website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation.  NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation.  © 2019 Vericel Corporation.  All rights reserved.

Global Media Contacts:David SchullRusso Partners LLCDavid.schull@russopartnersllc.com+1 212-845-4271 (office)+1 858-717-2310 (mobile)

Karen ChaseRusso Partners LLCKaren.chase@russopartnersllc.com+1 646-942-5627 (office)+1 917-547-0434 (mobile)

Investor Contacts:Chad RubinSolebury Troutcrubin@troutgroup.com+1 646-378-2947

Lee SternSolebury Troutlstern@troutgroup.com+1 646-378-2922